7 / 20
Page 40
conferenceseries
.com
Volume 7, Issue 4 (Suppl)
J Clin Trial
ISSN: 2167-0870 JCTR, an open access journal
Global Pharmacovigilance 2017
July 06-07, 2017
JULY 06-07, 2017 KUALA LUMPUR, MALAYSIA
8
TH
GLOBAL
Pharmacovigilance &
Drug Safety Summit
Biologic systemic therapy for moderate to-severe psoriasis: Emphasis on quality of life
Ali A Mustafa
King Fahd Medical City, KSA
Statement of the Problem:
Psoriasis is one of the autoimmune diseases of particular interest. It is a chronic, relapsing and
remitting inflammatory skin and joint disease that has a prevalence of 2-3% worldwide. Ethnic variations have been identified
and Caucasians are more likely to suffer from the disease. Chronic plaque psoriasis is a lifelong disease with a substantial impact
on the physical well-being and quality of a patient's life. As with all autoimmune diseases, the pathophysiology of psoriasis is
complicated and not yet fully understood. However, the signs and symptoms appear to be caused by hyper proliferation and
inflammation of epidermal cells. In psoriasis, an immunologic response involving T-lymphocytes and cytokines alters the
epidermal skin cell cycle resulting in psoriatic plaques. Like other autoimmune diseases a mixture of genetic, environmental
and behavioral influences are involved and or are associated with its development.
Methodology &Theoretical Orientation:
Randomized double-blind, placebo controlled studies have reviewed using the data
basis of Cochrane, Embase and PubMed. 4 biologic therapies (adalimumab, efalizumab, Etanercept and infliximab) which had
been thoroughly revised are now licensed for the treatment of moderate-to-severe psoriasis.
Conclusion & Significance:
Randomized double-blind, placebo controlled studies have demonstrated the short-term efficacy
and safety of all therapies for psoriasis. However, these data may not reflect practical day-to-day experience. Patients who
need such biologics are those who are suffering from the most severe forms of psoriasis. However, combinations of traditional
systemic and biologic therapies may be required. Treatments are time consuming and ineffective, and patients experience
side effect as the most negative aspect of current treatments. Recommendations are made for treatment is also reflected in the
Quality of Life research. Also, there is ample evidence that psoriasis can have a profound effect on patients’ functioning and
wellbeing.
amustafa@kfmc.med.saJ Clin Trial 2017, 7:4 (Suppl)
DOI: 10.4172/2167-0870-C1-017